Pilot: Insulin Sensitivity/Management in Hyperglycemic Patients in Perioperative Period ESRD/Non-ESRD
NCT03526536 is a phase 4 interventional trial sponsored by State University of New York - Downstate Medical Center. As of 18 Nov 2026, it was terminated. It studies IV Novolin R human insulin in Diabetes Mellitus and End-Stage Renal Disease. The registry lists an enrollment of 40 participants at 1 site in 1 country. The registry lists a start date of 1 May 2018 and a primary completion date of 3 Sept 2020.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03526536 |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | State University of New York - Downstate Medical Center |
| Enrollment | 40 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Diabetes Mellitus and End-Stage Renal Disease |
| Drugs | IV Novolin R human insulin |
| Start | 1 May 2018 |
| Primary completion | 3 Sept 2020 |
| Study completion | 3 Sept 2020 |
| Last update posted | 26 Oct 2020 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Ketan Shevde, MD
State University of New York - Downstate Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Suny Downstate Medical Center
Brooklyn
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03526536
Each answer restates registry values shown on this page.
What is NCT03526536?
NCT03526536 is a phase 4 interventional trial sponsored by State University of New York - Downstate Medical Center. It studies IV Novolin R human insulin in Diabetes Mellitus and End-Stage Renal Disease.
Who leads NCT03526536?
The registry names Ketan Shevde, MD (principal investigator, State University of New York - Downstate Medical Center) as the overall official.
Where does NCT03526536 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03526536 study?
The registered drug and biological interventions are IV Novolin R human insulin.
When did NCT03526536 end?
The registry lists a primary completion date of 3 Sept 2020 and a study completion date of 3 Sept 2020. The sponsor last updated the record on 26 Oct 2020.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.